NASDAQ · Biotechnology

ERNA (ERNA) Stock

$3.35 -3.46% NASDAQ: ERNA Healthcare

Valuation

MetricValue
Price$3.35
Market Cap$1.05M
P/E Ratio0.01
P/B Ratio1.11
P/S Ratio0.00
EPS (TTM)$-56.00
52-Week High$71.50
52-Week Low$3.18
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-2505.61%
ROA-81.20%
ROCE-300.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.06
Current Ratio1.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$1.0M$0
Operating Profit$-114.0M$-33.0M$-21.0M$-16.0M$-9.0M
Net Profit$-123.0M$-25.0M$-22.0M$-45.0M$-14.0M
EPS$-1415.25$-201.50$-102.00$-39.25$-56.00
Op Margin——-31080.9%-2693.1%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$32.0M$22.0M$49.0M$5.0M$6.0M
Total Liabilities$6.0M$10.0M$47.0M$4.0M$3.0M
Cash$17.0M$11.0M$8.0M$2.0M$2.0M
Borrowings$3.0M$4.0M$42.0M$1.0M$0

Latest News

Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA) InvestorsHub · Jul 15, 2026 Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination MT Newswires · Jul 15, 2026 Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry GlobeNewswire · Jul 15, 2026 Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026 GlobeNewswire · Jul 14, 2026 Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients GlobeNewswire · Jun 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-23.0M$-21.0M$-20.0M$-16.0M$-7.0M
Investing Cash Flow$-23.0M$0$0$-1.0M$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$15.0M$-1.0M$-4.0M$-10.0M$0
Free Cash Flow$-24.0M$-21.0M$-20.0M$-16.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA0.16
FCF Yield-355.32%
Quick Ratio2.89
Interest Coverage—
Return 1Y-85.98%
Return 3Y-99.36%
Return 5Y-99.99%

Ownership

Insiders Held41.74%
Institutions Held10.16%
Institutions Float Held17.44%
Institutional HolderSharesReport Date
Bleichroeder LP80,0002026-03-31
Dauntless Investment Group, LLC 24,4982026-03-31
Corient Private Wealth LLC17,5242026-03-31
Geode Capital Management, LLC9,7782026-03-31
Xtx Topco Ltd2,1742026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAPAdaptimmune Therapeutics plc $0.05 -3.00% -0.16 $75.16M 0.00%
AEMD $0.57 +6.51% -0.02 $430885 0.00%
AEONAEON Biopharma, Inc. $0.24 -5.50% -0.05 $2.80M 0.00%
DWTX $1.81 +3.14% 1.42 $3.45M 0.00%
LNAILunai Bioworks Inc. $2.29 -1.93% -0.04 $10.36M 0.00%

About ERNA

ERNA is led by CEO Sanjeev Luther, employs 6 people, headquartered in US, publicly traded since 1991.

ERNA stock trades at $3.35 with a market capitalization of $1.05M. The stock is valued at a price-to-earnings (P/E) ratio of 0.01, price-to-book of 1.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.18 and $71.50, and currently trades 95.3% below its 52-week high.

On profitability, ERNA generates a return on equity (ROE) of -2505.61%, return on capital employed of -300.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides